| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 3382- | ART/DHA, | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
| - | Review, | Var, | NA |
| 3383- | ART/DHA, | Dihydroartemisinin: A Potential Natural Anticancer Drug |
| - | Review, | Var, | NA |
| 3389- | ART/DHA, | Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers |
| - | Review, | Var, | NA |
| 3345- | ART/DHA, | Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells |
| - | in-vitro, | GBM, | NA |
| 3391- | ART/DHA, | Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug |
| - | Review, | Var, | NA |
| 5381- | ART/DHA, | Artemisitene triggers calcium-dependent ferroptosis by disrupting the LSH-EWSR1 interaction in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | NCM460 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT8 |
| 5380- | ART/DHA, | Artemisinin and Its Derivatives as Potential Anticancer Agents |
| - | Review, | Var, | NA |
| 5379- | ART/DHA, | Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance—from immune microenvironment crosstalk to therapeutic translation |
| 5378- | ART/DHA, | Natural Agents Modulating Ferroptosis in Cancer: Molecular Pathways and Therapeutic Perspectives |
| - | Review, | Var, | NA |
| 5377- | ART/DHA, | Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein |
| - | in-vitro, | AML, | NA |
| 5376- | ART/DHA, | Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW48 | - | in-vitro, | BC, | MDA-MB-453 |
| 5129- | ART/DHA, | Evidence for the Involvement of Carbon-centered Radicals in the Induction of Apoptotic Cell Death by Artemisinin Compounds |
| - | in-vitro, | AML, | HL-60 |
| 5137- | ART/DHA, | Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin |
| - | vitro+vivo, | ESCC, | Eca109 |
| 5130- | ART/DHA, | Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 2575- | ART/DHA, | docx, | Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC |
| - | in-vitro, | Lung, | H23 |
| 2573- | ART/DHA, | effects_of_halofuginone_and_artemisinin_in_colorectal_cancer_cells">Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 2574- | ART/DHA, | Artemisinin: A Promising Adjunct for Cancer Therapy |
| - | Review, | Var, | NA |
| 2576- | ART/DHA, | AL, | The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo |
| - | in-vitro, | OS, | MG63 | - | in-vivo, | NA, | NA |
| 2577- | ART/DHA, | Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives |
| - | Review, | Var, | NA |
| 2578- | ART/DHA, | RES, | Synergic effects of artemisinin and resveratrol in cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa |
| 2580- | ART/DHA, | VitC, | Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells |
| - | in-vitro, | AML, | NA |
| 2581- | ART/DHA, | PB, | Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells |
| - | in-vitro, | AML, | NA |
| 2582- | ART/DHA, | 5-ALA, | Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity |
| - | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT116 |
| 2461- | ASA, | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis |
| - | Review, | NA, | NA |
| 5409- | ASA, | Role of aspirin in cancer prevention |
| - | Review, | Var, | NA |
| 1028- | ASA, | Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development |
| - | vitro+vivo, | Ovarian, | NA |
| 1142- | Ash, | Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer |
| - | Review, | BC, | MCF-7 | - | NA, | BC, | MDA-MB-231 | - | NA, | Nor, | HMEC |
| 3175- | Ash, | SFN, | Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 3155- | Ash, | Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera |
| - | Review, | Var, | NA |
| 3160- | Ash, | Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal |
| - | Review, | Var, | NA |
| 3166- | Ash, | Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives |
| - | Review, | Var, | NA |
| 1369- | Ash, | Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis |
| - | in-vitro, | Melanoma, | U266 |
| 1370- | Ash, | Withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species |
| - | in-vitro, | Lung, | A549 |
| - | in-vitro, | AML, | HL-60 |
| 1373- | Ash, | Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells |
| - | in-vitro, | Kidney, | Caki-1 |
| 1355- | Ash, | Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HMEC |
| 1357- | Ash, | Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | GL26 |
| 1358- | Ash, | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
| - | Review, | Var, | NA |
| 1360- | Ash, | immuno, | Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | H1650 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| - | in-vitro, | Liver, | HUH7 | - | in-vivo, | Liver, | HUH7 |
| 1364- | Ash, | Withaferin a Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress |
| - | in-vitro, | Bladder, | J82 |
| 1365- | Ash, | Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vitro, | Oral, | CAL27 |
| 1433- | Ash, | SFN, | A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2001- | Ash, | Withania somnifera: from prevention to treatment of cancer |
| - | Review, | Var, | NA |
| 5173- | Ash, | 2DG, | Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | T47D |
| 5175- | Ash, | Withaferin A Induces Proteasome Inhibition, Endoplasmic Reticulum Stress, the Heat Shock Response and Acquisition of Thermotolerance |
| - | in-vitro, | Cerv, | CCL-102 |
| 5384- | AsP, | MEL, | Synergistic Anticancer Effect of Melatonin and Ascorbyl Palmitate Nanoformulation: A Promising Combination for Cancer Therapy |
| - | in-vivo, | Var, | NA |
| 5389- | AsP, | Tras, | ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLS |
| 4818- | ASTX, | MEL, | Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 4804- | ASTX, | Astaxanthin in cancer therapy and prevention (Review) |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid